Iterion Therapeutics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Iterion Therapeutics Inc. - overview
Established
2010
Location
Houston, TX, US
Primary Industry
Pharmaceuticals
About
Founded in 2010 and based in Houston, Texas, Iterion Therapeutics, trading under the name Betacat Pharmaceuticals, Inc. , operates as a biopharmaceutical company that develops novel targeted cancer therapeutics designed to treat a person with cancer. The company was co-founded by Rahul Aras, Steve Horrigan, and Sunil Sharma, and in February 2021, Iterion Therapeutics Inc. and Apollomics, Inc.
announced an exclusive collaboration and license agreement to develop and commercialize tegavivint in Greater China. In February 2021, the company received USD 17 million in Series B funding from Lumira Venture, Santé Ventures, Venture Investors, GPG Ventures, and Viva BioInnovator. The company offers a cancer treatment called "Tegavivint" a beta-catenin and Wnt gene expression modulator that prevents cancer gene activation and maintains regular tissue function. The company's product also provides anti-tumor activity in multiple pre-clinical models, including acute myeloid leukemia (AML) and non-small cell lung cancer (NSCLC).
Apollomics, Inc. and Iterion Therapeutics Inc. plans to expand clinical development for a potent and selective small-molecule targeting TBL1, a downstream target in the Wnt/ß-catenin signaling pathway.
Current Investors
Sante Ventures, Cancer Prevention & Research Institute of Texas, Clarevia Ventures
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.iteriontherapeutics.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Iterion Therapeutics Inc. - employee data
Iterion Therapeutics Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board Member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.